Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

>Dr. Philip M. Brown, senior vice president of clinical development at Lexicon.  "Rapid improvement in multiple parameters of diabetes, meaningful weight loss, a favorable safety profile and the fact that LX4211-treated patients exhibited improvements in clinically-important metabolic and cardiovascular parameters within four weeks on a single agent is remarkable."

The recently completed study was a four-week, randomized, double-blind, placebo-controlled study in 36 patients with type 2 diabetes.  Patients were randomized to receive either placebo (n=12) or LX4211, 150 mg (n=12) or 300 mg (n=12), once daily for 28 days.  Patients were sequestered, provided a controlled diet and monitored closely throughout the study period.

There was a marked decrease in fasting plasma glucose throughout the treatment period in both dose groups, with reductions at week four of 53.4 mg/dl and 65.9 mg/dl in the 150 mg and 300 mg dose groups, respectively, as compared to 15.1 mg/dl for placebo.  These decreases in fasting plasma glucose relative to placebo were statistically significant for both LX4211 dose groups (p=0.001 and p<0.001, respectively).  Notably, a substantial percentage (42%) of patients in the 300 mg dose group achieved fasting plasma glucose levels of <105 mg/dl at week four of dosing as compared to placebo (p=0.037).

Importantly, after only four weeks of dosing, average percent hemoglobin A1c (HbA1c), a measure of blood glucose levels over time, was significantly reduced by 1.15 in the 150 mg dose group (p=0.036) and by 1.25 in the 300 mg dose group (p=0.017), as compared to 0.49 in the placebo group.  HbA1c levels were reduced to less than or equal to 7% for half the patients in both dose groups; baseline levels were 8.22%, 8.50% and 8.20% for the 150 mg, 300 mg, and placebo groups, respectively. Patients in both dose groups also exhibited significantly improved glucose tolerance in resp
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  RXi ... biotechnology company focused on discovering and developing ... dermatology and ophthalmology, today announced that the Company,s ... , will present at the Jefferies 2015 ... 2015 at 11:30 a.m. EDT. Dr. Cauwenbergh ...
(Date:5/26/2015)... IRVING, Texas , May 26, 2015  Caris ... the promise of precision medicine, today announced the designation ... oncology practice in Virginia serving ... the US Oncology Network, as a center of excellence ... Medicine Network™ (Network). "As the largest ...
(Date:5/26/2015)... VANCOUVER, British Columbia , May 26, 2015 ... IMLFF), announced today that it has filed a ... and Trademark Office ("USPTO") relating to the treatment ... of natural cannabinoid compounds developed by InMed. ... Pharmaceuticals, Chief Scientific Officer, commented, "We are excited ...
Breaking Medicine Technology:RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 2RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 4Caris Life Sciences Designates Virginia Cancer Specialists as a Caris Center of Excellence 2Caris Life Sciences Designates Virginia Cancer Specialists as a Caris Center of Excellence 3Caris Life Sciences Designates Virginia Cancer Specialists as a Caris Center of Excellence 4InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 2InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 3
(Date:5/26/2015)... May 26, 2015 Sexual harassment and sexual ... IX is best known for creating opportunities in women's athletics, ... sexual assault response and prevention. In a recent episode of ... Sports Advocates explains what Title IX means for university ... in front of this issue to protect students. , In ...
(Date:5/26/2015)... Nagpur, India (PRWEB) May 26, 2015 ... April 2015, one of the leading online health and ... an impact to the online community. It has ... for people to read articles, watch videos, ask questions ... , The launch of the official Consumer Health Digest ...
(Date:5/26/2015)... IL (PRWEB) May 26, 2015 ... for the summer season, and thanks to the ... wellness solutions, more of their musicians are protecting ... , With over 400 participating groups, Etymotic’s Adopt-a-Band ... Earplugs by Etymotic are now for sale in ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Abington ... and Wellness, a physician practice with seven medical ... was the eighth primary-care site in the United ... patient-centered medical home by the National Committee for ... provides primary, preventative and sick care – including ...
(Date:5/26/2015)... 26, 2015 Irwin Gross, M.D., ... a hospital-wide Patient Blood Management (PBM) initiative at Eastern ... blood usage by more than 60 percent and improved ... in detail in an article in the May 2015 ... reduced perioperative red cell loss, less acute kidney injury ...
Breaking Medicine News(10 mins):Health News:Paul Greene Explores Title IX and College Sports on SCI TV 2Health News:Paul Greene Explores Title IX and College Sports on SCI TV 3Health News:Consumer Health Digest Official YouTube Channel: A Reliable Source of Health Information 2Health News:Marching Musicians Getting In Step With Hearing Protection 2Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3
... and Renal Replacement Therapy in Critical Care,Receive Significant ... Medical, Inc.,(Nasdaq: NXTM ), a leading manufacturer ... scientific meeting of the American Society,of Nephrology (ASN) ... the benefits and uses of daily home hemodialysis ...
... Cornerstone Therapeutics,Inc. (Nasdaq CM: CRTXD)*, a specialty ... medications for respiratory,disorders, today announced that, pursuant ... between Cornerstone BioPharma Holdings, Inc. and Critical,Therapeutics, ... chief executive,officer and a member of Cornerstone ...
... Forterus,Inc. (OTC Bulletin Board: FTER) today announced ... support to Footprints in Recovery, a North,Carolina-based ... sales and marketing support for Footprints in,Recovery,s ... Center Inc.,Forterus, fast growing, Southern California-based behavioral ...
... is often dependent on their ability to do deals successfully ... Comprehensive Assessment of Valuation in the Pharmaceutical Sector, the latest ... of deal-making, including valuations and royalty rate calculations. , ... ...
... Results include $141 million non-cash asset impairment charge, ... TUCSON, Ariz., Nov. 5 The Providence Service,Corporation ... third quarter of,2008 ended September 30, 2008. Included in ... $11.07 per share, asset impairment charge related,to the Company,s ...
... University Hospital became the first in Asia to offer the first robotic ... ... (PRWEB) November 5, 2008 -- Women who need to undergo surgery for ... painful, results in less scarring, allows them to get back on their ...
Cached Medicine News:Health News:NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting 2Health News:NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting 3Health News:NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting 4Health News:NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting 5Health News:Cornerstone Therapeutics Announces New Board of Directors 2Health News:Cornerstone Therapeutics Announces New Board of Directors 3Health News:Cornerstone Therapeutics Announces New Board of Directors 4Health News:Cornerstone Therapeutics Announces New Board of Directors 5Health News:Forterus Inc. Inks Agreement to Provide National Sales and Marketing Support for a North Carolina-Based Addiction Treatment Center 2Health News:Determining Valuations in Challenging Times 2Health News:Determining Valuations in Challenging Times 3Health News:Determining Valuations in Challenging Times 4Health News:Providence Service Corporation Releases Third Quarter Results 2Health News:Providence Service Corporation Releases Third Quarter Results 3Health News:Providence Service Corporation Releases Third Quarter Results 4Health News:Providence Service Corporation Releases Third Quarter Results 5Health News:Providence Service Corporation Releases Third Quarter Results 6Health News:Providence Service Corporation Releases Third Quarter Results 7Health News:Providence Service Corporation Releases Third Quarter Results 8Health News:Providence Service Corporation Releases Third Quarter Results 9Health News:Providence Service Corporation Releases Third Quarter Results 10Health News:Providence Service Corporation Releases Third Quarter Results 11Health News:Providence Service Corporation Releases Third Quarter Results 12Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 2Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 3Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 4Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: